FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.

Abstract

Nonalcoholic fatty liver disease, also called metabolic dysfunction-associated steatotic liver disease, is the most common liver disease worldwide and has no approved pharmacotherapy. Due to its beneficial effects on metabolic regulation, inflammation suppression, cell death prevention, and fibrogenesis inhibition, farnesoid X receptor (FXR) is widely accepted as a promising therapeutic target for nonalcoholic steatosis (NASH) or called metabolic dysfunction-associated steatohepatitis (MASH). Many FXR agonists have been developed for NASH/MASH therapy. Obeticholic acid (OCA) is the pioneering frontrunner FXR agonist and the first demonstrating success in clinical trials. Unfortunately, OCA did not receive regulatory approval as a NASH pharmacotherapy because its moderate benefits did not outweigh its safety risks, which may cast a shadow over FXR-based drug development for NASH/MASH. This review summarizes the milestones in the development of OCA for NASH/MASH and discuss its limitations, including moderate hepatoprotection and the undesirable side effects of dyslipidemia, pruritus, cholelithiasis, and liver toxicity risk, in depth. More importantly, we provide perspectives on FXR-based therapy for NASH/MASH, hoping to support a successful bench-to-clinic transition.

• Authors: Kang Wang, Yuecan Zhang, Guangji Wang, Haiping Hao, Hong Wang
• Journal: Medicinal research reviews (Med Res Rev) Vol. 44 Issue 2 Pg. 568-586 (Mar 2024) ISSN: 1098-1128 [Electronic] United States
• PMID: 37899676 (Publication Type: Journal Article, Review)
• Copyright: © 2023 Wiley Periodicals LLC.

Chemical References

• obeticholic acid
• Chenodeoxycholic Acid

Topics

• Humans
• Non-alcoholic Fatty Liver Disease (drug therapy)
• Chenodeoxycholic Acid (pharmacology, therapeutic use)